Eli Lilly Reaches $2.75 Billion Deal with Insilico to Bring AI-Developed Drugs to Market Eli Lilly just put a $2.75 billion price tag on the future of drug discovery. The pharmaceutical giant has reached a landmark licensing and collaboration agreement with Insilico Medicine, an AI-native biotech that uses generative models to design drug candidates from scratch — and the deal signals a fundamental shift in how the world’s most valuable pharma companies are thinking about their pipelines. ...